ABSTRACT
Background. Perinatally acquired hepatitis C virus (HCV) is the main source of pediatric HCV infection. However, the best time for initiation of screening and follow up of these infants is still unknown. Analysis of the clinical data of infants born to HCV-infected mothers, transmission rates, and pathway of HCV testing could be important for optimization of their management. Methods. Children of mothers with chronic HCV infection, who were observed between 1998 and 2013 at the pediatric infectious disease clinic for the first 18 months of their life, were eligible for enrollment. We analyzed the factors influencing initiation of HCV testing in these children and rate of HCV transmission as demonstrated by consecutive HCV antibody and HCV ribonucleic acid (RNA) amplification testing. Results. One hundred and forty-two mother-infant pairs were enrolled. The majority of mothers were intravenous drug users, had carried to term, and delivered vaginally. A high proportion of infants had at least 1 positive anti-HCV antibody assay without viremia. True HCV infection and intermittent viremia were recorded in 3.5% and 1.4% of infants, respectively. Initiation of HCV testing after 10 months of age was associated with a significant decline in the probability of obtaining a positive HCV antibody of maternal origin. Conclusions. The low likelihood for detection and confirmation of true HCV transmission before 10 months of age could challenge the early initiation of HCV screening of infants exposed to maternal HCV infection but may affect the parental need for early monitoring and counseling.
ABSTRACT
BACKGROUND: Kawasaki disease (KD) is a type of febrile self-limiting systemic vasculitis, which affects the coronary arteries (CA) and may cause cardiac ischemia during childhood and adult life. Intravenous immunoglobulin (IVIG) has become the standard therapy for KD. However, it is still uncertain if CA outcome is associated with the timing of IVIG administration with reference to fever onset. METHODS: The present study was designed to identify the risk for development and delay in resolution of CA abnormalities in association with IVIG administration within or after 10 days of KD onset. A retrospective analysis of clinical signs, laboratory data, and prospectively collected echocardiography (ECHO) results of 106 children hospitalized with KD was utilized. RESULTS: IVIG was administered to 86 (81.1%) patients within 10 days, and 20 (18.9%) patients received the first dose of IVIG after 10 days of illness. Among 23 (21.6%) patients who were diagnosed with CA lesions, 18 had a CA abnormality at initial ECHO, whereas they appeared after IVIG therapy in five patients. The risk for CA lesions on initial ECHO was higher among the patients who were admitted after 10 days of disease onset [odds ratio (OR) = 5.3, 95% confidence interval (CI) = 1.7-15.9] but comparable with the post-IVIG treatment group (OR = 3.1, 95% CI = 0.48-19.8). The age <1 year and erythrocyte sedimentation rate (ESR) > 40 mm/hour were associated with non-resolution of CA lesions within 9 weeks of KD onset. Overall, 95.6% of children had resolution of CA abnormalities within 6 months of onset of KD symptoms. CONCLUSION: The results of this study suggest that although IVIG treatment within 10 days is important to minimize development of cardiac pathology, neither occurrence of CA lesions in IVIG-treated children nor the time frame for resolution of established CA abnormalities was associated with the timing of IVIG administration. Age <1 year and high ESR (>40 mm/hour) predict a delay in resolution of CA lesions among children with KD.
Subject(s)
Coronary Artery Disease/etiology , Immunoglobulins, Intravenous/administration & dosage , Mucocutaneous Lymph Node Syndrome/complications , Mucocutaneous Lymph Node Syndrome/drug therapy , Child, Preschool , Coronary Artery Disease/diagnostic imaging , Coronary Vessels/diagnostic imaging , Drug Administration Schedule , Female , Humans , Infant , Male , Retrospective Studies , Risk Factors , UltrasonographySubject(s)
Antitubercular Agents/therapeutic use , Consciousness Disorders/etiology , Tuberculosis, Meningeal/diagnosis , Brain/diagnostic imaging , Child, Preschool , Humans , Infant , Magnetic Resonance Imaging , Male , Siblings , Tomography, X-Ray Computed , Tuberculosis, Meningeal/complications , Tuberculosis, Meningeal/drug therapyABSTRACT
OBJECTIVE: To determine factors affecting duration of chronic fatigue syndrome (CFS) in pediatric patients. METHODS: This Retrospective cohort consisted of patients with CFS at the regional referral infectious disease clinic for evaluation of fatigue in children and adolescents. Demographic, clinical, and laboratory data were analyzed to identify the impact on duration and severity of pediatric CFS. RESULTS: A total number of 53 predominantly white (98.1%) patients with CFS, aged 9-18 years, were included in the study. Other than fatigue, headaches and sleep disturbance were the most common symptoms of pediatric CFS. Seropositive status for Borrelia burgdorferi (B. burgdorferi) and Epstein-Barr virus (EBV) was identified in 66% of the patients with the diagnosis of CFS by CDC criteria. No association was found between the CFS symptoms, gender, or age at diagnosis and duration of fatigue symptoms. Duration of CFS was associated with high Body-Mass Index (BMI) in a regression model after adjustment for patient's age, gender, and seropositive status for B. burgdorferi and/or EBV (0.34 ± 0.15, P < 0.04). CONCLUSIONS: BMI is significantly associated with prolonged duration of CFS.
Subject(s)
Body Mass Index , Borrelia burgdorferi/immunology , Fatigue Syndrome, Chronic , Herpesvirus 4, Human/immunology , Overweight/complications , Adolescent , Antibodies, Bacterial/blood , Antibodies, Viral/blood , Child , Disease Progression , Fatigue Syndrome, Chronic/blood , Fatigue Syndrome, Chronic/complications , Fatigue Syndrome, Chronic/microbiology , Humans , Male , Pediatrics , Retrospective Studies , Risk FactorsABSTRACT
INTRODUCTION: Kawasaki disease is an idiopathic acute systemic vasculitis of childhood. Although it simulates the clinical features of many infectious diseases, an infectious etiology has not been established. This is the first reported case of Kawasaki disease following Rocky Mountain spotted fever. CASE PRESENTATION: We report the case of a 4-year-old girl who presented with fever and petechial rash. Serology confirmed Rocky Mountain spotted fever. While being treated with intravenous doxycycline, she developed swelling of her hands and feet. She had the clinical features of Kawasaki disease which resolved after therapy with intravenous immune globulin (IVIG) and aspirin. CONCLUSION: This case report suggests that Kawasaki disease can occur concurrently or immediately after a rickettsial illness such as Rocky Mountain spotted fever, hypothesizing an antigen-driven immune response to a rickettsial antigen.